

NEONATAL Medication Monograph

FAMOTIDINE

This document should be read in conjunction with this **DISCLAIMER**

Unrestricted: Any prescriber may initiate treatment as per guideline

Presentation	Vial: 20mg/2mL (SAS) Oral Mixture: Contact Pharmacy or use Famotidine 40mg Tablets		
Classification	Histamine (H2) receptor antagonist, which competitively inhibits the action of histamine thereby decreasing gastric acid secretion.		
Indication	 Short term treatment of gastric and duodenal ulcers Treatment of pathologic GI hypersecretory conditions e.g. Short Gut syndrome Short term symptomatic relief of gastro-oesophageal reflux 		
Dose	IV: 0.25mg to 0.5mg/ kg/ dose every 24 hours Oral: 0.5mg to 1mg/ kg/ dose every 24 hours		
Compatible Fluids	Sodium chloride 0.9%		
Adverse Reactions	Common: Diarrhoea, constipation Infrequent: Rash, vomiting, abdominal pain, Rare: NEC, Raised liver enzymes		
Preparation	IV: Dilute 2mL (20mg) of famotidine to a final volume 10mL with sodium chloride 0.9% Concentration is 20mg/10mL = 2mg/mL May be further diluted if required		

Famotidine - Neonatal Page 1 of 2

Preparation	Oral:			
	Use solution Prepared in Pharmacy if available			
	If solution not available – prepare the following solution using			
	famotidine 40mg tablets			
	 Dispense ONE famotidine tablet (40mg) in 20mL of water. Tablet will disperse within 2 minutes 			
	■ Concentration is 40mg/20mL = 2mg/mL			
	Discard any unused solution			
Administration	IV: Administer over at least 2 minutes			
	Oral: May be given at any time with regard to feeds.			
Storage	Vial: Refrigerate, do not freeze			
Notes	SAS Category A Form to be completed			
Notes References	SAS Category A Form to be completed Truven Health Analytics. Famotidine. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2020 Feb 05]. Available from: https://neofax.micromedexsolutions.com/			

Keywords	Famotidine, reflux, gastric secretion, H2 antagonist, ranitidine				
Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	February 2020	Version:	1.0		
Last reviewed:	February 2020	Next review date:	February 2023		
Endorsed by:	Neonatal Directorate Management Group	Date:	February 2020		
Standards Applicable:	NSQHS Standards: 1 Governance 3 Infection Control 4 Medication Safety;				
Printed or personally saved electronic copies of this document are considered uncontrolled.					
Access the current version from the WNHS website.					

[©] Department of Health Western Australia 2019